TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02516605
Drug: Part 1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered once daily for 28 days
Study: NCT02516605
Drug: Part 2: LJN452 Dose level 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJN452 capsules administered once a day for 12 weeks
Study: NCT02516605
Drug: Part 2: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to LJN452 administered once a day for 12 weeks
Study: NCT02516605
Drug: Part 2: LJN452 Dose level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJN452
Study: NCT00864968
Drug: Nabumetone 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
Study: NCT00864968
Drug: Nabumetone 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Teva formulated products under fasting conditions
Study: NCT00207363
Drug: induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
Study: NCT00408408
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 orally
Study: NCT00408408
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV
Study: NCT00408408
Drug: doxorubicin hydrochloride (Adriamycin)
Normalized name: doxorubicin hydrochloride Injection [Adriamycin]
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV
Study: NCT01164514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline.
Study: NCT01353898
Drug: MK-1972
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
Study: NCT01353898
Drug: Placebo to MK-1972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
Study: NCT00904449
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, 20mg, and 40mg PO
Study: NCT04362241
Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Normalized name: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone Acetate 1% ophthalmic drops
Study: NCT03942796
Drug: lyrica, vronogabic (pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
Study: NCT02108158
Drug: Azzalure
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04235959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02646501
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug
Study: NCT02167698
Drug: sedo-analgesia titration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00261599
Drug: AQUAVAN® (fospropofol disodium) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00859495
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
Study: NCT01220024
Drug: Placebo collagen Sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Collagen Sponge
Study: NCT02219750
Drug: switch twice-daily insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin
Study: NCT03570658
Drug: RO7049389
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
Study: NCT04611386
Drug: computerized tomography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti Factor Xa level
Study: NCT03570658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally at a dose and frequency matched to RO7049389.
Study: NCT00181272
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00298506
Drug: Multitherapy
Normalized name: Niacinamide 1.0 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL CREAM [rootree Mobitherapy Repair Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus,4mg/d, MMF 1.0g/d
Study: NCT02030067
Drug: RX-3117
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607904
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT00158301
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
Study: NCT02590627
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine
Study: NCT03279731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
Study: NCT02948998
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
Study: NCT04246996
Drug: gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
Study: NCT02875236
Drug: OctaplasLG®
Approvals — FDA: no, EMA: no, PMDA: no
Description: OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma.
Study: NCT02875236
Drug: Ringer-acetat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid used as standard of care.
Study: NCT00265876
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken daily every 4 weeks
Study: NCT04235673
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered drops
Study: NCT04049786
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose of simvastatin 40 mg are being administrated orally.
Study: NCT03388450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition without omega 3 fatty acid.
Study: NCT04391660
Drug: 0.5% sodium hypochlorite solution and 70% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
Study: NCT03241485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intrathecal given in the same manner as the intervention groups.
Study: NCT01617824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 4 days
Study: NCT01329991
Drug: PLX5622
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
Study: NCT01329991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for PLX5622
Study: NCT00746382
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT00602602
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04246684
Drug: 5FU; 2400 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/m2, 46h-civ, day 22, 36, 50, 64, 78, 92, 106, 120, 134 of therapy for Control arm
Study: NCT00553319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group
Study: NCT04246684
Drug: 5FU, 250 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/m2 per day, civ, on day 1-14, day 22-35 of radiotherapy;
Study: NCT04246684
Drug: 5FU, 2400 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/m2,46h-civ, d64, d78, d92, d106, d120, d134 of therapy
Study: NCT04246684
Drug: Folinic Acid, 400 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2h-civ day 22, 36, 50, 64, 78, 92, 106, 120, and 134 of therapyfor Control arm; 400 mg/m2, 2h-civ d 64, d78, d92, d106, d120, d134 of therapy for experimental arm
Study: NCT04246684
Drug: Capecitabine, 1000 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/m2 (twice daily) day1-14 every three weeks instead of 5FU optional
Study: NCT04246684
Drug: Capecitabine, 825 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 825 mg/m2 bid, per os, on day 1-14, 22-35 of RT instead of 5FU optional
Study: NCT03216525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
Study: NCT00508118
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: on bypass
Study: NCT01701531
Drug: RBCPF
Normalized name: Recombinant Bovine Chondroitin Polysulfate Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02751606
Drug: ferumoxtran-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
Study: NCT03373006
Drug: Axumin PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic amino acid uptake agent injection followed by imaging
Study: NCT00720291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
Study: NCT00377273
Drug: fluorouracil cream 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01229592
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
Study: NCT05737927
Drug: Glucose 8 g coated beads (47% w/w)
Normalized name: glucose 47 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study: NCT05737927
Drug: Glucose 12 g coated beads (47% w/w)
Normalized name: glucose 47 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study: NCT05737927
Drug: Glucose 12 g uncoated beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
Study: NCT05737927
Drug: Glucose 12 g coated beads (47% w/w)
Normalized name: glucose 47 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
Study: NCT01833351
Drug: IV Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.
Study: NCT01833351
Drug: IV Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.
Study: NCT00759551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
Study: NCT01728454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching capsules, orally, once daily for 18 weeks.
Study: NCT01190839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
Study: NCT02613910
Drug: Acetaminophen/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
Study: NCT03187314
Drug: Radiation
Normalized name: Miaderm Radiation Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
Study: NCT02828098
Drug: Part 1: BO-112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
Study: NCT02828098
Drug: Part 2: BO-112
Approvals — FDA: no, EMA: no, PMDA: no
Description: BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year.
Study: NCT03747497
Drug: contezolid acefosamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and oral contezolid acefosamil given twice a day for 10 to 14 days
Study: NCT02058966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules compounded to be of similar appearance to the active drugs
Study: NCT01926366
Drug: AZD6423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: AZD6423 Single or Multiple doses via infusion.
Study: NCT01926366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
Study: NCT03270280
Drug: Nigella Sativa Oil
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
Study: NCT03270280
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
Study: NCT00638248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. bolus
Study: NCT04524663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match camostat mesilate
Study: NCT04411316
Drug: Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
Study: NCT03940352
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03881488
Drug: CTX-471
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion every 2 weeks
Study: NCT01171898
Drug: ARN-509 (Phase 1)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
Study: NCT01171898
Drug: ARN-509 (Phase 2)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
Study: NCT01205464
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
Study: NCT01205464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
Study: NCT01855919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04024462
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study: NCT03937882
Drug: RGN-259
Approvals — FDA: no, EMA: no, PMDA: no
Description: A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
Study: NCT04024462
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
Study: NCT03937882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
Study: NCT01527760
Drug: Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)
Normalized name: Viscum album stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
Study: NCT03999203
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Study: NCT02534324
Drug: Antihypertensive meds
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
Study: NCT01963910
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: application to the other half of the upper lip following capsaicin cream removal
Study: NCT02314299
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01664975
Drug: GDPT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study: NCT01664975
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.